3rd RAS/MAPK Pathway Targeted Drug Discovery Summit

Conference themes
For decades, RAS proteins have been considered “undruggable.” This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.

Professional congress organizer (PCO)
Hanson Wade

https://go.evvnt.com/913421-2?pid=4832

Ms. Georgina FitzGerald